Derivation Web

source_f760a4be901a4d89

by researka:v2 · 2026-06-17 00:06:51.226633+04:00

# Research Synthesis: Fasting Regimens — full paper

## Abstract

Evidence-honesty note: 11/14 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on fasting regimens across 14 included source papers and 557 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 11 adjacent clinical sources, and 3 mechanistic or model-system sources, with 8 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals cluster in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that fasting regimens should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

## Methods

### Review type and protocol
This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-fasting_regimens-v06-DAILY-2026-06-16T19-52-05Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-16.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `fasting regimens aging`
- `fasting regimens older adults`
- `fasting regimens randomized controlled trial`
- `fasting aging`
- `fasting older adults`
- `fasting randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses fasting regimens.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 468 records in the receipt-candidate union, 180 were classified as source candidates and 14 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| Receipt candidate union | 468 |
| Classified source candidates | 180 |
| No extractable claims | 60 |
| None-only claim binding | 14 |
| Mixed partial-or-none claim-binding candidates | 112 |
| Partial-only claim-binding candidates | 45 |
| Strict high-confidence sources | 57 |
| Admitted final sources | 14 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.


| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Contextual Adjacent Evidence | n=10; claims=418 | no extracted directional signal in 8/10 sources | 5 indirect; 1 mechanistic; 4 review | limited corpus depth in this outcome class |
| Cardiometabolic | n=3; claims=97 | no extracted directional signal in 2/3 sources | 2 mechanistic; 1 review | limited corpus depth in this outcome class |
| Deficiency Prevalence | n=1; claims=42 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

### Contextual Adjacent Evidence Outcomes

10 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=8. Directness coding: indirect=5, mechanistic=1, review=4.

### Cardiometabolic Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: mechanistic=2, review=1.

### Deficiency Prevalence Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.


The corpus assembled for this synthesis is dominated by short-duration, indirect-outcome designs and does not contain a definitive long-term mortality or hard-cardiovascular-endpoint randomized trial of any fasting regimen in non-diabetic older adults. Monda 2026 reported a population descriptor of 12 months. Several entries that would normally be expected in a mature evidence base — large pragmatic trials of time-restricted eating in primary-prevention cardiometabolic cohorts, head-to-head regimen comparisons with hard endpoints, and adequately powered trials in frail or sarcopenic populations — are absent. The eight partial conflicts catalogued in the cross-study disagreement map, all of which are between Monda 2026 and a null or mixed finding from a different design, reflect this gap: without a long-horizon randomized anchor, the corpus cannot adjudicate whether the negative signals on contextual endpoints in Monda 2026 will attenuate, persist, or amplify with extended follow-up. Consequently, the headline conclusion that the Fasting anti-aging case is "incomplete" is a direct consequence of the trial record itself, not a rhetorical hedge; the missing study designs are the missing page of the evidence base, and the synthesis cannot manufacture them.

Several clinically relevant outcomes are touched by only a single source, which means they cannot be triangulated within the corpus and should be treated as hypothesis-generating rather than as synthesis-level findings. Shi 2025 is the sole source for the time-restricted-fasting + nicotinamide-mononucleotide combination on exercise capacity, and the underlying experiment is murine. Quan 2025 stands alone for the alternate-day-fasting / intestinal-epithelial-function claim in aging, again in animal tissue. Luciano 2026 provides the only genetic-modulation analysis of fasting-induced longevity, restricted to ten Collaborative Cross inbred mouse strains. Wang 2025 is the only entry anchoring adipose inositol monophosphate metabolism as a candidate mediator. When an outcome is supported by exactly one source, any single methodological caveat in that source — sample size, indirectness label, or population mismatch — propagates unchecked into the synthesis, and the reader should not interpret convergence across paragraphs as independent replication. The cross-study disagreement map further compounds this risk because several of the eight null-vs-negative conflicts are between Monda 2026 and a mechanistically adjacent but non-overlapping dataset, so within-corpus replication is structurally unavailable for the most contested claims.

The population specificity of the included sources narrows external validity in several clinically important directions. Monda 2026 enrolled adults with obesity and a BMI at or above the WHO 2000 obesity threshold, which limits generalization to normal-weight, metabolically healthy, or older underweight adults who might in principle benefit from — or be harmed by — fasting-induced sarcopenia. Jiao 2026 restricts its synthesis to middle-aged adults with overweight or obesity and does not provide stratum-specific estimates for older adults — the very population in which age-related gait-speed decline of approximately 0.05 m/s (Bohannon 1997) and sarcopenia cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) would be the relevant functional endpoints. Trials in adolescents, pregnant or lactating women, patients with chronic kidney disease or hepatic impairment, and adults with established eating-disorder risk are not represented, and the corpus offers no randomized evidence in frail older adults whose gait speed has already fallen below the 0.8 m/s mobility-risk threshold (Studenski 2011) or the 0.6 m/s severe-frailty cutoff (Cesari 2009). The translation of any headline effect to these groups is therefore a projection, not an inference supported by the curated data.

The endpoints measured across the corpus are predominantly mechanistic or short-term surrogate markers, and several hard outcomes that a clinician or guideline-writing body would require are simply not measured. The cardiometabolic-class sources (Fan 2026, Jiao 2026, Zhang 2026) report intermediate variables such as blood glucose, HbA1c, lipid fractions, and ketone bodies rather than event-level cardiovascular outcomes, which is the standard surrogate-versus-hard-endpoint caution (Ioannidis 2005). No source in the curated set reports incident diabetes, cardiovascular events, fractures, hospitalization, or mortality as a primary endpoint; the only mortality-adjacent signal is Luciano 2026, which is genetic-survival data in mice, not human all-cause mortality. The corpus also does not contain a sufficiently powered analysis of adverse events such as lean-mass loss, micronutrient deficiency, or hypoglycemia, even though Tavakoli 2025 surfaces a marginal adiponectin signal (P < 0.001) and the larger Tavakoli 2025 GRADE-assessed review explicitly notes mixed effects on weight-regulating hormones. Until these endpoints are measured, any claim that a fasting regimen "works" in a clinical sense outruns the data the synthesis can defend.

Several of the most attractive claims in the synthesis are supported only by mechanistic or preclinical evidence and therefore carry a documented mechanism-to-clinic gap. The synaptic-function and α-synuclein findings in Maleki 2026 are restricted to an acute amyloid-β rat model and cannot be transported to human Alzheimer disease prevention without an intermediate human biomarker study. Parnas 2026 frames β-hydroxybutyrate signaling and chromatin remodeling as cytoprotective, but its tissue source is murine and the eight p-values highlighted in the sources (e.g., P = 0.0025, P = 0.0161) describe molecular rather than clinical readouts. Zhang 2026 uses a persimthan-tannin mimetic of alternate-day fasting in obese mice, which adds an additional translational layer. Shi 2025 again is murine for the NMN-augmented time-restricted feeding signal. Across these entries, the synthesis is forced to report mechanism, not clinical effect, and the reader should not interpret the P < 0.01 and P < 0.001 results in the preclinical sources as evidence that any human anti-aging endpoint will move in the corresponding direction. Until the mechanistic findings are paired with adequately powered human trials on hard endpoints, the mechanism-to-clinic distance remains a binding limitation of every claim the synthesis puts forward.

## Conclusion

Across the 14 curated references, the evidence base for fasting regimens as an anti-aging or geroprotective intervention remains context-dependent rather than consolidated, and the integrating thesis — that mechanistic plausibility coexists with mixed or sparse human-RCT evidence, with boundary conditions still to be established — is supported by the weight of the sources. A central unresolved question, and one that the available sources do not answer, is whether surrogate-endpoint improvements observed over the typical 3–12 month follow-up windows translate into hard outcomes such as incident frailty, sarcopenia, or mortality, a caution consistent with the broader methodological concern that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).

For clinical practice today, the current evidence does not support marketing intermittent fasting, time-restricted feeding, or alternate-day fasting as a proven standalone anti-aging or geroprotective intervention, and pending further trials with hard endpoints in older adults, any off-label geroprotective use of these regimens should be considered investigational; this boundary is consistent with the pattern of mixed findings and the dominance of null or surrogate-only results in the sources. The evidence does support a hypothesis that fasting regimens may yield modest improvements in intermediate cardiometabolic markers in selected adults, particularly those with overweight, obesity, or metabolic syndrome, but the magnitude and durability of these effects across age strata, sexes, and genotypes remain to be confirmed (Xing 2026; Song 2025). General-health guidance — that adults who already wish to adopt a time-restricted eating pattern and tolerate it well can do so as one of several reasonable dietary approaches — is a separate question from claiming an evidence-based anti-aging effect, and clinicians should distinguish between these two framings when counseling patients. In short, the practice message is conservative: support tolerated, patient-preferred dietary patterns as part of standard cardiometabolic and general-health counseling, but do not promote fasting regimens as a validated anti-aging therapy outside the context of registered clinical trials.

## What This Synthesis Adds

This synthesis maps 14 included sources on Fasting across 3 outcome classes and 8 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 14 curated reference papers, the evidence base for Fasting shows a context-dependent profile. Negative signals appear in: contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Fasting anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs negative between Msane 2024 and Monda 2026 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Song 2025) emphasize convergent signals on Fasting. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 0 | 10 | mixed, negative, null | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P2 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 10 indirect sources; direction profile: mixed, negative, null |
| P3 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Fasting should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Additional corpus sources included animal/preclinical evidence; Song 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P = 0.001.
- Monda 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P < 0.001.
- Xing 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001 (off-summary).
- Jiao 2026; tier=B2; directness=review; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.01 (off-summary).
- Tavakoli 2025; tier=B2; directness=review; endpoint=deficiency prevalence; direction=null; representative statistic=P < 0.001 (off-summary).
- Shi 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001 (off-summary).
- Parnas 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001 (off-summary).
- Luciano 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.001 (off-summary).
- Quan 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Wang 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=mixed; claims=72.
- Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=negative; claims=96.
- Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=89.
- Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=60.
- The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial: outcome=deficiency prevalence; directness=review; tier=B2; direction=null; claims=42.
- Effects of Time-Restricted Fasting–Nicotinamide Mononucleotide Combination on Exercise Capacity via Mitochondrial Activation and Gut Microbiota Modulation: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31.
- Intermittent Fasting Enhances Genome Integrity and Cytoprotective Pathways via (BHB) β‐Hydroxybutyrate Signaling and Chromatin Remodeling: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=30.
- Genetic regulation of fasting-induced longevity effects: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.
- Alternate Day Fasting Enhances Intestinal Epithelial Function During Aging by Regulating Mitochondrial Metabolism: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10.
- Adipose Inositol Monophosphate Metabolism Is Associated with Fasting Regimen-Elicited Metabolic Benefits: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
- Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=1.
- Time‐Restricted Feeding Preserves Synaptic Function and Modulates Reelin and α ‐Synuclein in an Acute Amyloid‐ β Rat Model: A Comparative Study With Alternate‐Day Fasting: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=61.
- Uncovering shared and tissue-specific molecular adaptations to intermittent fasting in liver, brain, and muscle: outcome=cardiometabolic; directness=mechanistic; tier=C1; direction=unclear; claims=27.
- Simulation Effect and Mechanism of High-Polymeric Persimmon Tannin on Simulating Alternate-Day Fasting on Regulating Lipid Metabolism in Obese Mice: outcome=cardiometabolic; directness=mechanistic; tier=C1; direction=null; claims=10. Translational relevance to humans remains uncertain.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- In animal/preclinical evidence, severity 4 null vs negative: Msane 2024 vs Monda 2026; Monda 2026 (negative on contextual other) vs Msane 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Shi 2025 vs Monda 2026; Monda 2026 (negative on contextual other) vs Shi 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Quan 2025 vs Monda 2026; Monda 2026 (negative on contextual other) vs Quan 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Wang 2025 vs Monda 2026; Monda 2026 (negative on contextual other) vs Wang 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Monda 2026 vs Parnas 2026; Monda 2026 (negative on contextual other) vs Parnas 2026 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Monda 2026 vs Luciano 2026; Monda 2026 (negative on contextual other) vs Luciano 2026 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Monda 2026 vs Maleki 2026; Monda 2026 (negative on contextual other) vs Maleki 2026 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Monda 2026 vs Xing 2026; Monda 2026 (negative on contextual other) vs Xing 2026 (null on contextual other) — partial conflict



Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Perera 2006, ADA 2024, Tinetti 1988, Tancredi 2015.

## References

- **Monda 2026.** _Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity._ Nutrients, 2026. DOI: 10.3390/nu18020238. PMID: 41599851.
- **Xing 2026.** _Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Nutrients, 2026. DOI: 10.3390/nu18111799. PMID: 42280443.
- **Song 2025.** _Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation._ Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1664811. PMID: 41459076.
- **Maleki 2026.** _Time‐Restricted Feeding Preserves Synaptic Function and Modulates Reelin and α ‐Synuclein in an Acute Amyloid‐ β Rat Model: A Comparative Study With Alternate‐Day Fasting._ Journal of Nutrition and Metabolism, 2026. DOI: 10.1155/jnme/7185647. PMID: 42254080.
- **Jiao 2026.** _Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1772836. PMID: 41883415.
- **Tavakoli 2025.** _The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial._ Journal of Health, Population, and Nutrition, 2025. DOI: 10.1186/s41043-025-00834-1. PMID: 40176106.
- **Shi 2025.** _Effects of Time-Restricted Fasting–Nicotinamide Mononucleotide Combination on Exercise Capacity via Mitochondrial Activation and Gut Microbiota Modulation._ Nutrients, 2025. DOI: 10.3390/nu17091467. PMID: 40362776.
- **Parnas 2026.** _Intermittent Fasting Enhances Genome Integrity and Cytoprotective Pathways via (BHB) β‐Hydroxybutyrate Signaling and Chromatin Remodeling._ The FASEB Journal, 2026. DOI: 10.1096/fj.202503534R. PMID: 41811201.
- **Fan 2026.** _Uncovering shared and tissue-specific molecular adaptations to intermittent fasting in liver, brain, and muscle._ eLife, 2026. DOI: 10.7554/eLife.107332. PMID: 41995076.
- **Luciano 2026.** _Genetic regulation of fasting-induced longevity effects._ Genetics, 2026. DOI: 10.1093/genetics/iyag045. PMID: 41701627.
- **Quan 2025.** _Alternate Day Fasting Enhances Intestinal Epithelial Function During Aging by Regulating Mitochondrial Metabolism._ Aging Cell, 2025. DOI: 10.1111/acel.70052. PMID: 40168185.
- **Zhang 2026.** _Simulation Effect and Mechanism of High-Polymeric Persimmon Tannin on Simulating Alternate-Day Fasting on Regulating Lipid Metabolism in Obese Mice._ Nutrients, 2026. DOI: 10.3390/nu18101608. PMID: 42197068.
- **Wang 2025.** _Adipose Inositol Monophosphate Metabolism Is Associated with Fasting Regimen-Elicited Metabolic Benefits._ Biomolecules, 2025. DOI: 10.3390/biom15111514. PMID: 41301432.
- **Msane 2024.** _Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review._ Nutrients, 2024. DOI: 10.3390/nu16162692. PMID: 39203828.

### Background References

*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*

- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.
- **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594.
- **Perera 2006.** _Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749._ DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
- **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.
- **WHO 2000.** _World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000._ PMID: 11234459.
- **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15.
- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.
- **Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267.
- **Tancredi 2015.** _Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732._ DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.

{
  "article_type": "rapid_evidence_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "7c5ccb76-8350-42ae-8ce7-2d6860416cf3",
  "title": "Research Synthesis: Fasting Regimens \u2014 full paper"
}